Moomoo AI 已提取核心訊息
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of $150,000,000 of its common stock and pre-funded warrants to purchase shares of common stock. The offering is subject to completion and is dated February 28, 2024. The pre-funded warrants will be sold at the public offering price per share of common stock minus $0.0001, multiplied by the number of shares subject to the warrant, with an exercise price of $0.0001 per share. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' On February 27, 2024, the last reported sale price of Arcutis' common stock was $10.63 per share. The offering is expected to provide 14,111,006 shares, assuming an assumed public offering price of $10.63 per share. The pre-funded warrants...Show More
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of $150,000,000 of its common stock and pre-funded warrants to purchase shares of common stock. The offering is subject to completion and is dated February 28, 2024. The pre-funded warrants will be sold at the public offering price per share of common stock minus $0.0001, multiplied by the number of shares subject to the warrant, with an exercise price of $0.0001 per share. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' On February 27, 2024, the last reported sale price of Arcutis' common stock was $10.63 per share. The offering is expected to provide 14,111,006 shares, assuming an assumed public offering price of $10.63 per share. The pre-funded warrants will not be listed on any market, and there is no expectation for a trading market to develop. The offering involves risks, including the absence of an established market for the pre-funded warrants and the potential dilution to existing shareholders. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are acting as underwriters for the offering.
處於商業階段的生物製藥公司Arcutis Biotherapeutics宣佈發行1.5億美元的普通股和預先注資的認股權證，以購買普通股。此次發行有待完成，日期爲2024年2月28日。預先注資的認股權證將按普通股每股公開發行價格減去0.0001美元，乘以認股權證約束的股票數量出售，行使價爲每股0.0001美元。普通股在納斯達克全球精選市場上市，股票代碼爲 “ARQT”。2024年2月27日，Arcutis普通股最新公佈的銷售價格爲每股10.63美元。假設公開發行價格爲每股10.63美元，預計此次發行將提供14,111,006股股票。預先注資的認股權證不會在任何市場上市，交易市場預計不會發展。此次發行涉及風險，包括預先注資的認股權證缺乏既定市場，以及現有股東可能被稀釋。摩根士丹利、道明考恩、古根海姆證券、瑞穗和Needham & Company擔任此次發行的承銷商。
處於商業階段的生物製藥公司Arcutis Biotherapeutics宣佈發行1.5億美元的普通股和預先注資的認股權證，以購買普通股。此次發行有待完成，日期爲2024年2月28日。預先注資的認股權證將按普通股每股公開發行價格減去0.0001美元，乘以認股權證約束的股票數量出售，行使價爲每股0.0001美元。普通股在納斯達克全球精選市場上市，股票代碼爲 “ARQT”。2024年2月27日，Arcutis普通股最新公佈的銷售價格爲每股10.63美元。假設公開發行價格爲每股10.63美元，預計此次發行將提供14,111,006股股票。預先注資的認股權證不會在任何市場上市，交易市場預計不會發展。此次發行涉及風險，包括預先注資的認股權證缺乏既定市場，以及現有股東可能被稀釋。摩根士丹利、道明考恩、古根海姆證券、瑞穗和Needham & Company擔任此次發行的承銷商。
有用
沒用